Skip to main content

Table 1 Age standardized characteristics at blood draw/buccal cell collection and control selection

From: Genetic variability in IGF-1 and IGFBP-3 and body size in early life

  NHSI NHSII
  (n = 3499) (n = 1068)
Age at blood draw/buccal cell collection, mean (SD)a 59.6 (7.7) 44.9 (4.3)
Somatotype at age 5b, mean (SD) 2.3 (1.3) 2.5 (0.9)
Somatotype at age 10b, mean (SD) 2.5 (1.3) 2.8 (1.0)
BMI at age 18, mean (SD) 21.2 (2.7) 21.1 (2.2)
Birthweightb, N (%)   
 <5.5 lbs 329 (12.0) 84 (8.8)
 10+ lbs 79 (2.9) 12 (1.3)
DNA from blood, N (%) 3132 (89.5) 1068 (100)
Menopausal status/Post-menopausal hormone (PMH) use at blood draw/buccal cell collectionb, N (%)  
 Premenopausal 764 (24.0) 680 (68.2)
 Postmenopausal-PMH non-user 1574 (49.5) 136 (13.6)
 Postmenopausal-PMH user 843 (26.5) 182 (18.2)
Menopausal status/Post-menopausal hormone (PMH) use at reference dateb, N (%)  
 Premenopausal 508 (16.0) 479 (47.7)
 Postmenopausal-PMH non-user 1479 (46.8) 37 (3.7)
 Postmenopausal-PMH user 1171 (37.1) 487 (48.6)
  1. aValue is not age-standardized.
  2. bCalculated among those with known values.
  3. NHS:7% were missing information on somatotype at age 5, 6% were missing information on somatotype at age 10, and 22% were missing information on birthweight. 9% were missing menopausal status at blood draw and 9% were missing menopausal status at selection.
  4. NHSII:1% were missing information on somatotype at age 5, 1% were missing information on somatotype at age 10, and 11% were missing information on birthweight. 7% were missing menopausal status at blood draw and 6% were missing menopausal status at selection.